Bowel cancer breakthrough may benefit thousands of patients

July 18, 2014, Queen's University Belfast

Researchers at Queen's University have made a significant breakthrough that may benefit patients with bowel cancer.

Dr Sandra van Schaeybroeck and her team have discovered how two genes cause cells to become resistant to treatments used against the disease. The research, which was funded by Cancer Research UK, was published this month in the prestigious international journal Cell Reports.

The activity of the two genes, called MEK and MET, was uncovered when the researchers looked at all the different pathways and interactions taking place in bowel cancer cells.

Dr van Schaeybroeck and her group found that these bowel cancers switch on a survival mechanism when they are treated with drugs that target faulty MEK genes. But when the researchers added drugs that also block the MET gene, the bowel died.

The team are now testing a new approach to target these two genes in the most aggressive forms of bowel cancer in a European Commission funded clinical trial that is being led by Dr van Schaeybroeck.

Currently over 40,000 people are diagnosed with bowel cancer in the UK each year and over 16,000 patients die of the disease. More than half of patients develop the aggressive form of the disease which does not respond to standard therapy, the five year overall survival in this patient group is less than five per cent.

Study author Dr Sandra van Schaeybroeck, from the Centre for Cancer Research and Cell Biology (CCRCB) at Queen's University, said: "We have discovered how two key genes contribute to aggressive bowel cancer. Understanding how they are involved in development of the disease has also primed the development of a potential new treatment approach for this disease."

Queen's University Vice-Chancellor, Professor Patrick Johnston, said: "Understanding the that cause bowel cancer is a key focus of our research. Our discoveries in this deadly disease have identified a new route to clinical application for cancer patients."

Professor David Waugh, Director of the CCRCB at Queen's, said: "The publication of this research by Dr van Schaeybroeck and her team demonstrates our commitment to performing excellent science here in Belfast that can be directly translated to the clinic."

The clinical trial, which is called MErCuRIC and is due to start in September, will deliver personalised medicine to Northern Irish patients and from other European countries. Overall, the pan European collaborative effort will involving 13 research/clinical teams from nine European countries.

Explore further: Sunshine vitamin ups bowel cancer survival odds, study finds

More information: "ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer." Sandra Van Schaeybroeck, Murugan Kalimutho, Philip D. Dunne, Robbie Carson, Wendy Allen, Puthen V. Jithesh, Keara L. Redmond, Takehiko Sasazuki, and others. Cell Reports, Vol. 7, Issue 6, p1940–1955. Published online: June 12, 2014

Related Stories

Sunshine vitamin ups bowel cancer survival odds, study finds

July 9, 2014
Bowel cancer patients with high levels of vitamin D in their blood are more likely to survive the disease, a study shows.

New type of bowel cancer discovered

April 15, 2013
(Medical Xpress)—A unique sub-type of bowel cancer has been discovered which has a worse outcome than other types of colon cancer and is resistant to certain targeted treatments, according to research published today in ...

New target for aggressive bladder cancer

July 10, 2014
An international team of scientists have discovered a faulty process in certain bladder cancers that could point to new ways to treat patients with an aggressive form of the disease.

Family history of bowel cancer increases odds of survival

March 20, 2013
A new study that combines genetic information on bowel cancer with NHS patient outcome data has found a link between family history of the disease and a better chance of survival, published in the British Journal of Cancer.

New type of molecular switch could turn up the volume on bowel cancer treatment

November 5, 2012
(Medical Xpress)—A new type of molecular switch can boost common chemotherapy drugs to destroy bowel cancer cells, according to research presented today (Monday) at the NCRI Cancer Conference in Liverpool.

Double dose of genes can trigger poor cancer survival

January 23, 2014
(Medical Xpress)—Cancer Research UK scientists have shown that accidental DNA doubling in bowel cancer cells could predict which patients have potentially poor survival and help doctors plan their treatment, according to ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.